Zobrazeno 1 - 10 of 33 pro vyhledávání: '"Richard J Davenport"'
1
Akademický článek
Experiences of remote consulting for patients and neurologists during the COVID-19 pandemic in Scotland
Autor: Richard J Davenport, Maria Stavrou, Eva Lioutas, Joanna Lioutas
Publikováno v: BMJ Neurology Open, Vol 3, Iss 2 (2021)
Background Remote consulting is an emerging model in managing chronic neurological conditions and has been widely implemented during the COVID-19 pandemic. The objective of this national survey was to investigate the initial experiences of remote con
Externí odkaz: https://doaj.org/article/23232eedcfaa4addbf7842bac392bacf
Zobrazit plný text záznamu
2
Visual loss with chronic meningeal and systemic inflammation
Autor: Lucy Kinton, Frederick R Burgess, Stephen Madill, Neeraj Dhaun, Desmond P. Kidd, Peter M Fernandes, David M. Hunt, Helen J. Lachmann, Euan McRorie, Richard J Davenport
Publikováno v: Practical Neurology. 22:64-70
A 46-year-old man presented with worsening vision in the context of long-standing optic disc changes, bilateral sensorineural hearing loss, chronic aseptic meningitis, rash, arthralgia and raised inflammatory markers. The differential diagnoses of ne
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25eca2789bea0033bda4df5c13992c5c
https://doi.org/10.1136/practneurol-2021-003066
Zobrazit plný text záznamu
5
Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6)
Autor: Jennifer Turney, Henriëtte M. G. Willems, Philip J. Mitchell, Vivienne Allen, Alan G. Hendrick, Takashi Ito, Jenny Reeves, Susanne Wright, Ilka Müller, Richard J. Davenport, Richard Bazin, Stephen Wilkinson, Philip Leonard, Helen Heffron, Steve Irving
Publikováno v: Journal of Medicinal Chemistry. 59:8094-8102
Fatty acid binding protein 6 (FABP6) is a potential drug discovery target, which, if inhibited, may have a therapeutic benefit for the treatment of diabetes. Currently, there are no published inhibitors of FABP6, and with the target believed to be am
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb461ea8115897027e5a13fb8162307c
https://doi.org/10.1021/acs.jmedchem.6b00869
Zobrazit plný text záznamu
6
Selective FFA2 Agonism Appears to Act via Intestinal PYY to Reduce Transit and Food Intake but Does Not Improve Glucose Tolerance in Mouse Models
Autor: K. Real, Matt Barnes, Richard J. Davenport, Helen M. Cox, Robert Newman, Stuart Stafford, Helen Heffron, Johannes Grosse, Sarah Forbes, Gareth Coope
Publikováno v: Diabetes. 64:3763-3771
Free fatty acid receptor 2 (FFA2) is expressed on enteroendocrine L cells that release glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) when activated by short-chain fatty acids (SCFAs). Functionally GLP-1 and PYY inhibit gut transit, increase gl
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9691959fca26e3bb88814cbebc62e29c
https://doi.org/10.2337/db15-0481
Zobrazit plný text záznamu
7
1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction
Autor: Hannah E. Canning, Natalie A. Webster, Robert J. Skene, Andrew Paul Ayscough, Susanne Wright, Saleh Ahmed, Livermore David, Anthony Ivetac, Steven James Wilkens, Natasha Kinsella, David Harrison, Robert Downham, Barker Gregory, Alan G. Hendrick, Kerry Jenkins, Richard J. Davenport
Publikováno v: Journal of medicinal chemistry. 60(13)
Herein we describe the identification of 4-{[1,2,4]triazolo[1,5-a]pyridin-5-yl}benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc98a639af3a638d0e61c52f5b0c4bc6
https://pubmed.ncbi.nlm.nih.gov/28594552
Zobrazit plný text záznamu
8
Treating obesity: is it all in the gut?
Autor: Richard J. Davenport, Susanne Wright
Publikováno v: Drug Discovery Today. 19:845-858
Obesity is a leading cause of preventable mortality worldwide, with current strategies for treatment including life-style changes, pharmacological intervention and bariatric surgery. With pharmacological intervention showing at best modest patient be
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::728b985f467efebc68812dd256a81bec
https://doi.org/10.1016/j.drudis.2013.10.025
Zobrazit plný text záznamu
9
Identification of a novel GPR81-selective agonist that suppresses lipolysis in mice without cutaneous flushing
Autor: Richard J. Davenport, Sarah Bousba, Mathew Leveridge, David Harrison, Junji Matsui, Taku Sakurai, Louise Dickson, Kazumasa Ogawa, Matt Barnes, Stephen Robert Mack, Johannes Grosse, Parmar Alka, Laura Parton, Jennifer Cameron, Andy Sykes, Stuart Stafford
Publikováno v: European Journal of Pharmacology. 727:1-7
GPR81, which exhibits a high degree of homology with GPR109a, has been recently identified as a lactate receptor. Similar to GPR109a, the activation of GPR81 by lactate suppresses lipolysis, suggesting that GPR81 may be a potential drug target for tr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93662ada30b352aaba9afd5483b1214c
https://doi.org/10.1016/j.ejphar.2014.01.029
Zobrazit plný text záznamu
10
Visual disturbance with systemic symptoms: old lessons revisited
Autor: Kirsty MacLean, Megan E Hume, Euan McRorie, Richard J Davenport, Peter M Fernandes
We describe a retired physician who presented with visual disturbance and systemic symptoms. The presence of general malaise, headache and scalp tenderness, with raised inflammatory markers, suggested that giant cell arteritis (GCA) was the likely di
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b16f4ed99c03932a401cfbef727e143
https://europepmc.org/articles/PMC5093805/
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje